Citigroup has downgraded Haemonetics Corp (HAE) to Neutral from Buy, reflecting a shift in sentiment regarding the company's outlook. The action, taken on December 10, 2025, comes as the firm currently trades at $84.73 per share.
This downgrade suggests increased caution, potentially due to competitive pressures, market conditions, or execution risks that could impact the company's performance. Haemonetics, headquartered in Boston, Massachusetts, specializes in the development and distribution of hematology products and solutions, employing 3,023 full-time staff. The company operates across various medical markets, including blood and plasma component collection, surgical suites, and hospital transfusion services.
With a market capitalization of $3.9 billion, Haemonetics has a trailing P/E ratio of 23.46 and an EPS of 3.43. Analysts are anticipating upcoming earnings reports, with estimates of $1.25 EPS and $341.1 million in revenue due on August 5, 2026.
Analyst ratings serve as professional opinions based on research and financial models. While these assessments can provide useful perspectives, they reflect assumptions that may not materialize as expected. Investors should consider a range of factors, including company fundamentals, competitive positioning, and industry trends, when making decisions. Analyst views are just one of many inputs in the investment process.
The recent downgrade is part of a broader trend in analyst actions, with a consensus rating of Buy still prevailing among 15 analysts, including 5 Strong Buy and 7 Buy ratings.